Phase 2 Trial of MP0317 in Bile Duct Cancer Doses First Patients
MOLN is trading near its 52-week low of $3.41 (15% above the low) on light trading volume (0.2× avg).
Summary
Molecular Partners has dosed the first patients in a Phase 2 proof-of-concept study of MP0317 combined with standard-of-care chemoimmunotherapy for first-line advanced cholangiocarcinoma. The randomized TACTIC trial will enroll 75 patients across nine French sites, with a 2:1 randomization favoring the experimental arm. This follows the positive Phase 1 data published in Nature Cancer and the recent pipeline update highlighting MP0317's potential. The trial's design targets a meaningful improvement in 12-month progression-free survival, a high bar in this difficult-to-treat cancer. A data update is expected in 2027, with completion in 2028, and a trial-in-progress poster will be presented at ESMO 2026. The news marks a concrete step forward for the company's lead immuno-oncology asset, though the small market cap means the program's success is critical.
At the time of this announcement, MOLN was trading at $3.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $157.6M. The 52-week trading range was $3.41 to $5.36. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.